Clene

Clene Share Buybacks

The Share Buybacks of Clene (CLNN) as of Nov 16, 2026 is 11.77 M USD. In the previous year, Share Buybacks was 7.80 M USD — a change of 50.84% (higher).

Share Buybacks

11.77 MUSD

YoY

50.84%

Last updated:

Share Buybacks of Clene is 2022 11.77 M USD. Share Buybacks of Clene was 2021 7.80 M USD. It decreases by 50.84% higher compared to the previous year.

The Clene Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2017
0.00 USD
Jan 1, 2020
31.12 M USD
Jan 1, 2021
7.80 M USD
Jan 1, 2022
11.77 M USD
The Clene Share Buybacks history
YEARShare BuybacksYoY
11.77 MUSD+50.84%
7.80 MUSD-74.92%
31.12 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Share Buybacks of Clene is 11.77 M USD in 2022.

Share Buybacks of Clene changed from 7.80 M USD to 11.77 M USD, representing a 50.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Clene since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clene

All Key Metrics — Clene